Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML

Shin Mineishi, MD, John Magenau, MD, Hiromi Tobai, MD, Attaphol Pawarode, MD, Edward M. Peres, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Harry P Erba, MD, PhD, Lisa Kujawski, MD, Gregory Yanik, MD, James Ferrara, MD, John E. Levine, MD, MS

Blood (2010) 116 (21): 35.

https://doi.org/10.1182/blood.V116.21.35.35

Published: 2010

Journal Articles

Acquired Genomic Copy Number Aberrations and Survival In CLL

Sami Malek, MD, Brian Parkin, MD, Edward M. Peres, MD, Moshe Talpaz, MD, Mark S. Kaminski, MD, Lisa Kujawski, MD, Roxanne Collins, Kerby Shedden, Peter Ouillette

Blood (2010) 116 (21): 1713.

https://doi.org/10.1182/blood.V116.21.1713.1713

Published: 2010

Journal Articles

A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.

Sami Malek, MD, Brian Parkin, Peter Ouillette, Lisa Kujawski, MD, Harry Paul Erba, MD, PhD, Erica L. Campagnaro, MD, Mark S. Kaminski, MD, Kerby Shedden, Kamlai Saiya-Cork

Blood (2009) 114 (22): 2324.

https://doi.org/10.1182/blood.V114.22.2324.2324

Published: 2009

Journal Articles

Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia.

Sami Malek, MD, Peter Ouillette, Yin Wang, Yan Liu, Whitney Wright, Diane Roulston, Amanda L Dressel, RN, BSN, Judith Karp, Paula Bockenstedt, MD, Ammar Al-Zoubi, MD, Moshe Talpaz, Lisa Kujawski, MD, Yang Liu, Kerby Shedden, Sajid Shakhan, Cheng Li, Ph.D, Harry Paul Erba, MD, PhD, Brian Parkin

Blood (2009) 114 (22): 165.

https://doi.org/10.1182/blood.V114.22.165.165

Published: 2009

Journal Articles

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Shin Mineishi, MD, John Magenau, MD, Attaphol Pawarode, MD, Timothy Buck, Dawn Jones, RN, Koji Kato, MD, David Frame, Pharm.D, Lisa Kujawski, MD, Harry Paul Erba, MD, PhD, Yasser Khaled, MD, Edward M. Peres, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Gregory A. Yanik, MD, Thomas Braun, PhD, James L.M. Ferrara, MD, John E. Levine, MD

Blood (2008) 112 (11): 2150.

https://doi.org/10.1182/blood.V112.11.2150.2150

Published: 2008

Journal Articles

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.

Sami N. Malek, MD, Peter Ouillette, MT, ASCP, Lisa Kujawski, MD, Sanjeev Shangary, PhD, Moshe Talpaz, MD, Mark Kaminski, MD, Harry Erba, Kerby Shedden, PhD, Shaomeng Wang, PhD, Chris Saddler, BS

Blood (2007) 110 (11): 224.

https://doi.org/10.1182/blood.V110.11.224.224

Published: 2007

Journal Articles

Genomic Complexity Identifies Patients with Agressive Chronic Lymphocytic Leukemia.

Sami N. Malek, MD, Peter Ouillette, MT, ASCP, Harry Erba, MD, PhD, Chris Saddler, BS, Andrzej Jakubowiak, MD, Mark Kaminski, MD, Kerby Shedden, PhD, Lisa Kujawski, MD

Blood (2007) 110 (11): 489.

https://doi.org/10.1182/blood.V110.11.489.489

Published: 2007

NARROW

Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML

Acquired Genomic Copy Number Aberrations and Survival In CLL

A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.

Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia.

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.

Genomic Complexity Identifies Patients with Agressive Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML

Acquired Genomic Copy Number Aberrations and Survival In CLL

A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.

Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia.

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.

Genomic Complexity Identifies Patients with Agressive Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only